POINT Biopharma Global Inc PNT

NAS: PNT | ISIN: US7305411099 26/12/2023

12,50 USD (+0,16%)

(+0,16%) 26/12/2023

Toon enkel gratis nieuws

27 december 2023 · Lilly Completes Acquisition of POINT Biopharma · Persbericht

18 december 2023 · Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 · Persbericht

4 december 2023 · Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 · Persbericht

8 november 2023 · Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma · Persbericht

26 oktober 2023 · Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm · Persbericht

19 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VSTO, OLK, PNT · Persbericht

13 oktober 2023 · Moore Kuehn Encourages TWNK, LVOX, ACER, and PNT Investors to Contact Law Firm · Persbericht

10 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWLI, MRTX, SLGC, PNT · Persbericht

10 oktober 2023 · ALERT: The M&A Class Action Firm Continues Investigating the Merger - RPT, SP, ORTX, PNT · Persbericht

4 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PNT, KITT, TRHC · Persbericht

3 oktober 2023 · Shareholder Alert: Ademi LLP investigates whether POINT Biopharma Global, Inc. has obtained a Fair Price in its transaction with Eli Lilly · Persbericht

3 oktober 2023 · Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe